DF
AGIO icon

Donoghue Forlines’s Agios Pharmaceuticals AGIO Stock Holding History

Donoghue Forlines’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-47,902
Closed -$2.29M – 63
2019
Q4 		$2.29M Buy
+47,902
New +$1.81M 0.35% 93

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Donoghue Forlines's AGIO Position: Q1 2020 in Review

Donoghue Forlines sold out of Agios Pharmaceuticals (AGIO) in Q1 2020, closing a stake of 47,902 shares — an estimated $2.29M sold.

Donoghue Forlines first reported a position in AGIO in Q4 2019 and held it in 1 quarter. The position peaked at $2.29M in Q4 2019. 197 funds tracked by Wall St. Rank hold AGIO as of Q1 2020.

  • Donoghue Forlines reported no remaining Agios Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Donoghue Forlines sold 47,902 Agios Pharmaceuticals shares in Q1 2020, an estimated $2.29M.
  • Donoghue Forlines first reported a position in Agios Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Donoghue Forlines's Agios Pharmaceuticals position peaked at $2.29M in Q4 2019.
  • 197 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2020.

Based on Donoghue Forlines's 13F filing for Q1 2020, filed 12 May 2020.